Logo image of TPST

TEMPEST THERAPEUTICS INC (TPST) Stock Fundamental Analysis

USA - NASDAQ:TPST - US87978U2078 - Common Stock

8.57 USD
-1.05 (-10.91%)
Last: 11/12/2025, 2:53:56 PM
Fundamental Rating

2

Taking everything into account, TPST scores 2 out of 10 in our fundamental rating. TPST was compared to 531 industry peers in the Biotechnology industry. The financial health of TPST is average, but there are quite some concerns on its profitability. TPST has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TPST had negative earnings in the past year.
TPST had a negative operating cash flow in the past year.
TPST had negative earnings in each of the past 5 years.
TPST had a negative operating cash flow in each of the past 5 years.
TPST Yearly Net Income VS EBIT VS OCF VS FCFTPST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -210.49%, TPST is doing worse than 90.40% of the companies in the same industry.
With a Return On Equity value of -568.14%, TPST is not doing good in the industry: 77.97% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -210.49%
ROE -568.14%
ROIC N/A
ROA(3y)-78.49%
ROA(5y)-71.6%
ROE(3y)-175.41%
ROE(5y)-142.93%
ROIC(3y)N/A
ROIC(5y)N/A
TPST Yearly ROA, ROE, ROICTPST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TPST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TPST Yearly Profit, Operating, Gross MarginsTPST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

TPST has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TPST has been increased compared to 5 years ago.
The debt/assets ratio for TPST has been reduced compared to a year ago.
TPST Yearly Shares OutstandingTPST Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
TPST Yearly Total Debt VS Total AssetsTPST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TPST has an Altman-Z score of -23.06. This is a bad value and indicates that TPST is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TPST (-23.06) is worse than 85.69% of its industry peers.
TPST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.06
ROIC/WACCN/A
WACCN/A
TPST Yearly LT Debt VS Equity VS FCFTPST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

TPST has a Current Ratio of 2.30. This indicates that TPST is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TPST (2.30) is worse than 71.19% of its industry peers.
A Quick Ratio of 2.30 indicates that TPST has no problem at all paying its short term obligations.
TPST has a worse Quick ratio (2.30) than 68.93% of its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
TPST Yearly Current Assets VS Current LiabilitesTPST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

TPST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.76%, which is quite impressive.
EPS 1Y (TTM)50.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TPST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.15%
EPS Next 2Y7.8%
EPS Next 3Y9.22%
EPS Next 5Y11.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TPST Yearly Revenue VS EstimatesTPST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2028 2030 2031 2032 50M 100M 150M 200M
TPST Yearly EPS VS EstimatesTPST Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2K -4K -6K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TPST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TPST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TPST Price Earnings VS Forward Price EarningsTPST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TPST Per share dataTPST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.8%
EPS Next 3Y9.22%

More info and screens

0

5. Dividend

5.1 Amount

TPST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPEST THERAPEUTICS INC

NASDAQ:TPST (11/12/2025, 2:53:56 PM)

8.57

-1.05 (-10.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners18.87%
Inst Owner Change-31.15%
Ins Owners0.12%
Ins Owner Change0%
Market Cap38.05M
Revenue(TTM)N/A
Net Income(TTM)-36.05M
Analysts43.33
Price Target9.18 (7.12%)
Short Float %3.62%
Short Ratio2.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.21%
Min EPS beat(2)22.1%
Max EPS beat(2)76.31%
EPS beat(4)3
Avg EPS beat(4)20.93%
Min EPS beat(4)-20.6%
Max EPS beat(4)76.31%
EPS beat(8)5
Avg EPS beat(8)9.95%
EPS beat(12)8
Avg EPS beat(12)10.82%
EPS beat(16)11
Avg EPS beat(16)10.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6
P/tB 6
EV/EBITDA N/A
EPS(TTM)-10.05
EYN/A
EPS(NY)-16.34
Fwd EYN/A
FCF(TTM)-7.52
FCFYN/A
OCF(TTM)-7.52
OCFYN/A
SpS0
BVpS1.43
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -210.49%
ROE -568.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.49%
ROA(5y)-71.6%
ROE(3y)-175.41%
ROE(5y)-142.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z -23.06
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.31%
Cap/Depr(5y)60.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.18%
EPS Next Y33.15%
EPS Next 2Y7.8%
EPS Next 3Y9.22%
EPS Next 5Y11.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.55%
EBIT Next 3Y-27.03%
EBIT Next 5Y-26.77%
FCF growth 1Y-18.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.73%
OCF growth 3YN/A
OCF growth 5YN/A

TEMPEST THERAPEUTICS INC / TPST FAQ

What is the ChartMill fundamental rating of TEMPEST THERAPEUTICS INC (TPST) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TPST.


Can you provide the valuation status for TEMPEST THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to TEMPEST THERAPEUTICS INC (TPST). This can be considered as Overvalued.


Can you provide the profitability details for TEMPEST THERAPEUTICS INC?

TEMPEST THERAPEUTICS INC (TPST) has a profitability rating of 0 / 10.


Can you provide the financial health for TPST stock?

The financial health rating of TEMPEST THERAPEUTICS INC (TPST) is 5 / 10.